Traws Pharma doses first subject in Phase 2 COVID study of ratutrelvir; top-line data by year-end 2025

Traws Pharma, Inc.

First subject dosed in Phase 2 study of ratutrelvir, a ritonavir-free anti-viral for newly diagnosed COVID.
Two trials: non-inferiority versus PAXLOVID and a single-arm study for PAXLOVID-ineligible patients.
Top-line results from both Phase 2 studies expected by year-end 2025.
Ratutrelvir is once-daily, single tablet for 10 days; aims to reduce rebound and Long COVID risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.